Rare types of helper T cells uncovered
Researchers have created a new T cell atlas which could aid the development of novel drug therapies for immune-mediated diseases.
List view / Grid view
Researchers have created a new T cell atlas which could aid the development of novel drug therapies for immune-mediated diseases.
A new assay has been developed which enables the detailing of intact proviral genomes of under-studied HIV strains.
In this Q&A, Associate Director, Research at Immunocore, Dr Ana Pereira Ribeiro, talks about IMC-R117C, a T cell receptor bispecific immunotherapy directed towards a novel target, PIWIL1, and about to enter Phase I testing in colorectal and gastrointestinal cancers.
A new immunotherapy approach combining co-engineered T cells and antibodies enhances phagocytosis of tumour cells.
In this Q&A, we had the privilege of speaking to COUR Pharmaceuticals’ CEO John Puisis. He offers insights into how their innovative immune-modifying nanoparticle platform differs from traditional approaches for treating immune-mediated diseases.
Following Zymeworks’ presentation at AACR 2024, in this Q&A, Dr Nina Weisser explains how the next generation trispecific T cell engager platform with integrated CD28 costimulation is engineered to tackle solid tumours.
In this Q&A, Dr DaeYong Lee discusses how a new method for building up natural immune response could lead to new immunotherapy drugs with safer toxicity profiles.
The new organoids demonstrate a greater diversity of TECs in culture and are capable of maturing T cells.
Scientists found that preventing the effects of prostaglandin E2 could be an effective therapy to overcome tumour defence.
Researchers have developed a new tool called ‘Uveal Melanoma Immunogenic Score’ to predict which patients will respond to adoptive therapy.
Evidence indicating that FOXO1 plays a unique role in promoting T cell longevity could result in more effective CAR T cell therapies.
The proof-of-concept study could lead to a cure for HIV that inactivates diverse strains across multiple cellular contexts.
The new findings could lead to a therapeutic target for immune-related disorders, like multiple sclerosis.
A single change in the amino acid structure of the transmembrane segment can either enhance or diminish the inhibitory function of PD-1 in immune responses.
A new study shows that changes in clonal dominance characterises T-cell memory against multiple COVID-19 variants following mRNA vaccinations.